Pilatus Biosciences (the “Company”), a biotechnology company focused on shaping the future of cancer treatment through trailblazing First-in-class biologics focusing on metabolic checkpoints, today announces that the Company will present new preclinical data of its anti-CD36 antibody program, PLT012, at the upcoming American Association for Cancer Research’s Annual Meeting (“AACR 2024”). The data will be shared in a poster presentation entitled “Revitalizing Anti-Tumor Immunity Through PLT012 Monoclonal Antibody, Targeting CD36 for Metabolic Rewiring in the Tumor Microenvironment”, on April 8^th, 2024 (Abstract #2370)

Details of the poster presentation are as follows:

Full text of the abstracts has been released on the AACR website and the posters will be available on the Company's website.About CD36 and PLT012CD36, a fatty acid transporter, has been reported to be up-regulated in both malignant cells and tumor-associated immune cells, including regulatory T cells, tumor-associated macrophages and CD8+ T cells, to adjust the metabolic preference, which allow the cells to adapt in the lipid-enriched tumor microenvironment (“TME”). This CD36-mediated adaption not only alters metabolic regulations, but also impacts the immune cell properties to construct an immunosuppressive TME with increased exhausted tumor-reactive CD8+ T cells and immunosuppressive regulatory T cells.

PLT012, a humanized anti-CD36 antibody, was developed to block CD36-mediated fatty acid uptake without interfering with other physiological functions. PLT012 aims to disarm intratumoral Treg and boost tumor-reactive CD8+ T cells in the tumor microenvironment, leading to remarkable anti-tumor efficacy and synergistic effects with current ICB therapies. More detailed data will be presented at AACR 2024.